Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Qingfang Miao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6359-741X; OpenAlex author ID A5112112481. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 4 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 8

  1. hIMB1636-LDM, a novel anti-TROP2 ADC, exerts potent antitumor efficacy in pancreatic cancer via direct cytotoxicity and immune activation. Last author DOI 10.1016/j.bcp.2026.118222↗
  2. hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer. Last author DOI 10.1021/acs.jmedchem.3c01210↗
  3. Theranostic application of 64Cu/177Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models. Co-author DOI 10.1007/s00259-022-05954-y↗
  4. The recombinant defensin/HSA fusion protein that inhibits NF-κb associated with intensive macropinocytosis shows potent efficacy against pancreatic cancer. Co-author DOI 10.1016/j.bcp.2022.115057↗
  5. Development of a novel multi-functional integrated bioconjugate effectively targeting K-Ras mutant pancreatic cancer. Co-author DOI 10.1016/j.jpha.2021.07.001↗
  6. Rational Design and Systemic Appraisal of an EGFR-Targeting Antibody-Drug Conjugate LR-DM1 for Pancreatic Cancer. Co-author DOI 10.1021/acs.jmedchem.1c01920↗
  7. Promoted antitumor therapy on pancreatic cancer by a novel recombinant human albumin-bound miriplatin nanoparticle. Co-author DOI 10.1016/j.ejps.2021.106000↗
  8. A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer. Co-author DOI 10.18632/oncotarget.11170↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yong‐Su Zhen · 5 shared papers, 2016–2026 · strength 0.86
  2. D X Zhou · 1 shared paper, 2026 · strength 0.29
  3. Ying Wang · 1 shared paper, 2026 · strength 0.29
  4. Weijin Sheng · 2 shared papers, 2016–2022 · strength 0.23
  5. Liang Li · 1 shared paper, 2022 · strength 0.17
  6. Yangyang Wang · 1 shared paper, 2022 · strength 0.17
  7. Liping Sun · 1 shared paper, 2023 · strength 0.17
  8. Yibo Du · 1 shared paper, 2022 · strength 0.16
  9. Xiaofei Wang · 1 shared paper, 2022 · strength 0.16
  10. Mei Zhu · 1 shared paper, 2022 · strength 0.15
  11. Yucheng Wang · 1 shared paper, 2022 · strength 0.15
  12. Wenpeng Huang · 1 shared paper, 2022 · strength 0.14
  13. Xu Yang · 1 shared paper, 2022 · strength 0.14
  14. Lei Kang · 1 shared paper, 2022 · strength 0.14
  15. Cuicui Li · 1 shared paper, 2022 · strength 0.14
  16. Jigang Yang · 1 shared paper, 2022 · strength 0.14
  17. Jie Ma · 1 shared paper, 2021 · strength 0.13
  18. Guimin Xia · 1 shared paper, 2021 · strength 0.13
  19. Dan Wang · 1 shared paper, 2021 · strength 0.13
  20. Xiaowei Wang · 1 shared paper, 2021 · strength 0.13
  21. Yue Du · 1 shared paper, 2016 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.